FDA OK's Trial of Transition's AZD-103
Posted on: Tuesday, 1 August 2006, 12:01 CDT
Transition Therapeutics said Tuesday the U.S. Food and Drug Administration cleared a phase 1 trial of AZD-103 for Alzheimer's.
Transition said it anticipates beginning the trial in September. Healthy volunteers will receive placebo or an escalating dose of AZD-103.
The company said a previous phase 1 trial of AZD-103 announced in April has completed enrollment. The company said in a statement that it plans to release data from the study in the near future.
A study in a transgenic mouse model of Alzheimer's disease indicated AZD-103 reduced the accumulation of amyloid beta and amyloid beta plaques in the brain. The compound also reduced learning deficits in the mice.
Source: United Press International
Related Articles
- Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease
- Elan and Transition Start Phase II Trial for Alzheimer's Drug
- Elan and Transition Therapeutics Dose First Patient in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease
- Elan and Transition Enter Alzheimer's Agreement
- Transition Alzheimer's Drug Proves Safe in Phase I Trial
- Transition Gets Go-Ahead for Clinical Trials of Alzheimer's Drug
- FDA Provides Clearance to Initiate Phase I Clinical Trial With Alzheimer's Disease Drug Product AZD-103
- Transition Alzheimer's Trial Given Green Light By Canadian Regulator
- Transition Reports Positive Preclinical Alzheimer's Data
 |
 |
User Comments (0)
RSS Feeds